Overview

COVID-19 Methylene Blue Antiviral Treatment

Status:
Active, not recruiting

Trial end date:
2021-11-08

Target enrollment:

Participant gender:

Summary

This is a pilot study of a single-center, blind, randomized, placebo-controlled, parallel-group study testing for the efficacy and safety of Methylene blue when administered topically as a 0.02% solution for nasopharyngeal and oropharyngeal irrigation in COVID-19 patients requiring hospitalization.

Phase:

Phase 2

Details

Lead Sponsor:

Irkutsk Scientific Center of the Siberian Branch of the Russian Academy of Sciences

Collaborator:

Irkutsk State Medical University

Treatments:

Methylene Blue